John Stahl
Partner, US Pricing and Market Access
John Stahl is a Partner with Clarivate’s Commercial Strategy Consulting team and leads the US Pricing and Market Access practice.
John leverages over 20 years of deep healthcare knowledge as well as a broad range of market access and commercialization experience to effectively deliver strategic and actionable insights to biopharmaceutical and medtech clients. John has been with Clarivate for 10+ years, and during this time, he has supported clients with the development of market access landscape assessments, evidence generation and value communication strategies, pricing and contracting strategies, and account engagement strategies and tactics. His experience spans numerous TAs, with a concentration in cell and gene therapy, rare disease, oncology, immunology, and neurology conditions.
Prior to joining Clarivate, John spent over ten years in the pharmaceutical industry working for Johnson & Johnson and Novartis, in a variety of positions of increasing responsibility, including business analytics, business development, sales, marketing, and managed markets.
John graduated from Duke University with a B.A. in Economics and a B.A. in German. He also completed the Certificate program in Markets and Management Studies.
Latest news
Clarivate Unveils Citation Laureates 2025 – Highlighting Nobel-Class Research with Global Impact
22 Researchers Recognized, Including First Citation Laureate Based in Mainland China London, U.K. September 25, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the Citation…
Clarivate Announces the India Research Excellence – Citation Awards 2025
The 10th Edition to Honor Researchers and Institutions for Pioneering Contributions to Research London, U.K. September 19, 2025. Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced…
BioWorld by Clarivate Celebrates 35 Years of Trusted Biopharma and Medtech Journalism
Award-winning independent news and analysis continue to guide life sciences leaders through rapid scientific and market change London, U.K. — September 18, 2025 — BioWorld, published by Clarivate Plc (NYSE:CLVT),…